2-(4-bromonaphthalen-1-yl)ethan-1-ol | 90867-05-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(4-bromonaphthalen-1-yl)ethan-1-ol
• 英文别名: 1-Bromo-4-(2-hydroxyethyl)naphthalene；2-(4-bromonaphthalen-1-yl)ethanol
• CAS: 90867-05-3
• 化学式: C₁₂H₁₁BrO
• 分子量: 251.123
• InChiKey: YGJYDMYLSBQUHX-UHFFFAOYSA-N

物化性质

• 沸点：
  382.8±17.0 °C(Predicted)
• 密度：
  1.476±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(4-bromonaphthalen-1-yl)ethan-1-ol 在 吡啶 、 氯化亚砜 、 氯氟磺酰 、 五氟化锑 作用下， 以 乙醚 为溶剂， 生成 1-bromo-4-ethylnaphthalene
  参考文献：
  名称：

  Stable carbocations. 255. .alpha.-Ethylenehaloarenium ions

  摘要：

  DOI：

  10.1021/jo00190a016
• 作为产物：
  描述：

  1-萘乙醇 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以84%的产率得到2-(4-bromonaphthalen-1-yl)ethan-1-ol
  参考文献：
  名称：

  Dearomative Allylation of Naphthyl Cyanohydrins by Palladium Catalysis: Catalyst-Enhanced Site Selectivity

  摘要：

  A dearomative allylation of naphthyl cyanohydrins with allyl borates and allyl stannanes under palladium catalysis was developed. At the initial stage of this study, the dearomative reaction (C4 substitution of the aromatics) was competing with benzyl substitution. To circumvent this issue, the use of palladium and meta-disubstituted triarylphosphine as the catalyst in a 1:1 ratio was found to enhance the site selectivity, furnishing the desired dearomatized products. Further derivatizations of products were also successful.

  DOI：

  10.1021/acs.orglett.0c00897

文献信息

• Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial Fibrillation
  作者：Bertrand Plouvier、Gregory N. Beatch、Grace L. Jung、Alexander Zolotoy、Tao Sheng、Lilian Clohs、Terrance D. Barrett、David Fedida、Wei Q. Wang、Jeff J. Zhu、Yuzhong Liu、Shlomo Abraham、Leah Lynn、Ying Dong、Richard A. Wall、Michael J. A. Walker

  DOI：10.1021/jm0604528

  日期：2007.6.1

  A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological

  描述了制备为潜在抗心律不齐药的一系列2-氨基烷基醚。本发明的化合物是混合的钠和钾离子通道阻滞剂，并且在缺血引起的心律不齐的大鼠模型中表现出抗心律不齐的活性。结构活性研究导致鉴定了三种化合物5、18和26，这是根据它们的特定体内电生理特性选择的，用于两种犬心房颤动（AF）模型的研究。在这两种模型中，这三种化合物均可转化为AF，但仅化合物26被证明具有口服生物利用度。将外消旋物26拆分为其相应的对映体40和41，然后对这些对映体进行生物学测试，结果导致选择（1S，
• Glucagon antagonists/inverse agonists
  申请人：Novo Nordisk A/S

  公开号：US06613942B1

  公开（公告）日：2003-09-02

  Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

  本发明公开了包含中央腙基结构的非肽化合物及其合成方法。这些化合物具有拮抗胰高血糖素肽激素作用的作用。
• [EN] DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS<br/>[FR] DÉRIVÉS DE DÉSOXYNOJIRIMYCINE EN TANT QU'INHIBITEURS DE GLUCOSIDASE
  申请人：EMERGENT PRODUCT DEV GAITHERSBURG INC

  公开号：WO2022011211A1

  公开（公告）日：2022-01-13

  The present application provides novel iminosugars and their use as glucosidase inhibitors. The present inventors have discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition where inhibiting glucosidase may be important.

  本申请提供了新颖的亚胺糖以及它们作为葡萄糖苷酶抑制剂的用途。本发明人发现某些脱氧诺吉霉素衍生物可能有效地抑制葡萄糖苷酶。特别是，这些脱氧诺吉霉素衍生物可能对治疗需要抑制葡萄糖苷酶的疾病或病况有用。
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] ANTAGONISTES/AGONISTES INVERSES DU GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO1999001423A1

  公开（公告）日：1999-01-14

  Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.

  非肽化合物包含一个中心肼基结构，并且其合成方法。这些化合物作用是拮抗胰高血糖素肽激素的作用。
• Synthesis and Structure−Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography
  作者：Peter G. Willis、Olga A. Pavlova、Svetlana I. Chefer、D. Bruce Vaupel、Alexey G. Mukhin、Andrew G. Horti

  DOI：10.1021/jm0502743

  日期：2005.9.1

  A new series of CB1 ligands with high binding affinity (K-i = 0.7-100 nM) and moderate lipophilicity (cLogD(7.4)) in the range of 2.1-4.5 has been synthesized. A structure-activity relationship study demonstrated that for the studied set of aminoalkylindoles, the molecular dipole of the ground state conformation within the series was inversely related to the affinity. The racemic ligand with highest affinity (0.7 nM), 3-(4-fluoronaphthoyl)-1-(N-methylpiperidin-2-ylmethyl)indole, was radiolabeled with F-18. This radioligand specifically labeled CB, receptors in mouse brain and accumulated in regions of high versus low CB1 receptor density in a ratio of 1.6. The displaceable radioactivity of one enantiomer in the brains of mice determined in a pretreatment study using the CB, antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) was nearly double that of the racemate for the same determination; therefore, the active enantiomer is a candidate for PET studies in animals. A pretreatement study for the other enantiomer found no displaceable radioactivity in the same group of mice; this result suggested the enantiomer was inactive.